Human monocytes/macrophages express three classes of receptors for IgG: Fc␥RI, Fc␥RII, and Fc␥RIII. The expression and function of these receptors has been extensively studied with the exception of one, Fc␥RIIb. While the mRNA for Fc␥RIIb has been detected in human monocytes, the protein has remained elusive. Studies in mouse models indicated that the macrophage Fc␥RIIb serves to down-regulate Fc␥R-mediated phagocytosis and immune complex-induced inflammation. Fc␥RIIb has also been shown to modulate the action of cytotoxic antibodies against tumors in mouse models. Hence, an understanding of how Fc␥RIIb expression is regulated is of great importance. Here we demonstrate for the first time Fc␥RIIb protein expression and function in human monocytes. We also report that the expression of Fc␥RIIb is highly up-regulated by interleukin-4, a Th2 cytokine, and that the up-regulation of Fc␥RIIb results in a decrease in the phagocytic efficiency of interleukin-4-treated THP-1 cells. Furthermore co-clustering Fc␥RIIb with Fc␥RIIa resulted in enhanced phosphorylation of the inositol phosphatase SHIP, association of SHIP with Shc, and phosphorylation of additional proteins around 120 and 60 -65 kDa, with a concomitant attenuation of Akt activation. We, therefore, propose that Fc␥RIIb serves to inhibit Fc␥RI/ IIa-mediated macrophage activation using SHIP as its effector.
Human monocytes/macrophages express three classes of receptors for IgG: Fc␥RI, Fc␥RII, and Fc␥RIII. The expression and function of these receptors has been extensively studied with the exception of one, Fc␥RIIb. While the mRNA for Fc␥RIIb has been detected in human monocytes, the protein has remained elusive. Studies in mouse models indicated that the macrophage Fc␥RIIb serves to down-regulate Fc␥R-mediated phagocytosis and immune complex-induced inflammation. Fc␥RIIb has also been shown to modulate the action of cytotoxic antibodies against tumors in mouse models. Hence, an understanding of how Fc␥RIIb expression is regulated is of great importance. Here we demonstrate for the first time Fc␥RIIb protein expression and function in human monocytes. We also report that the expression of Fc␥RIIb is highly up-regulated by interleukin-4, a Th2 cytokine, and that the up-regulation of Fc␥RIIb results in a decrease in the phagocytic efficiency of interleukin-4-treated THP-1 cells. Furthermore co-clustering Fc␥RIIb with Fc␥RIIa resulted in enhanced phosphorylation of the inositol phosphatase SHIP, association of SHIP with Shc, and phosphorylation of additional proteins around 120 and 60 -65 kDa, with a concomitant attenuation of Akt activation. We, therefore, propose that Fc␥RIIb serves to inhibit Fc␥RI/ IIa-mediated macrophage activation using SHIP as its effector.
Clustering of the Fc␥ receptors (Fc␥R)
1 on monocytes/macrophages by immune complexes initiates a series of intracellular biochemical events that are necessary for induction of phagocytosis. The phagocytic process itself is accompanied by the generation of tissue-damaging products such as inflammatory cytokines, reactive oxygen species, and lysosomal enzymes.
Thus, like all immune responses the phagocytic response must be subject to homeostatic control exerted by inhibitory receptors and/or inhibitory enzymes and resulting in a tempered immune response. Indeed in mouse models it has been established that expression of Fc␥RIIb, an inhibitory receptor, results in down-regulation of Fc␥R-mediated phagocytosis (1) . That a similar regulation might occur in human macrophages has been speculated but not confirmed. Human macrophages but not murine macrophages express the ITAM-bearing Fc␥RIIa whose extracellular and transmembrane domains are similar to Fc␥RIIb (2), thereby complicating the detection and analysis of expression and function of Fc␥RIIb in these cells.
In humans, Fc␥RIIb are expressed as two alternatively spliced products, Fc␥RIIb1 and -b2 (3). A 13-amino acid motif within the cytoplasmic tail of Fc␥RIIb termed ITIM (immunoreceptor tyrosine-based inhibitory motif), confers the ability to inhibit cellular activation mediated by ITAM-bearing immunoreceptors (4 -6) . Inhibition occurs only when Fc␥RIIb is coclustered with an ITAM-bearing receptor. The role of Fc␥RIIb as a negative regulator of immune cell function is demonstrated in mice genetically altered to be deficient in the expression of this receptor. Thus, Fc␥RIIb knockout mice display hypergammaglobulinemia and augmented IgG-mediated anaphylaxis in response to antigenic challenge (1, 7) . The inhibitory function of Fc␥RIIb is mediated by the inositol phosphatase SHIP (8) , which associates with the phosphorylated ITIM of Fc␥RIIb via the SHIP SH2 domain (9 -11) . Association of SHIP with Fc␥RIIb results in the tyrosine phosphorylation and recruitment of SHIP to the cell membrane where it subsequently hydrolyzes PtdIns(3,4,5)P 3 to PtdIns(3,4)P 2 (9) . PtdIns-P 3 is required for binding and activation of plextrin homology domain containing molecules such as Btk, a Tec family tyrosine kinase (12) , Vav, a guanine exchange factor for the low molecular weight GTP-binding proteins of the Rho family (13) , and Akt, a serine/threonine kinase involved in the protection of cells from apoptosis (14, 15) . SHIP consumption of PtdIns-P 3 thus leads to the down-regulation of the above plextrin homology domain containing enzymes, and blocks the ensuing biologic responses.
Fc␥RIIb has also been shown to associate with the hematopoetic cell-specific protein-tyrosine phosphatase SHP-1 both in in vitro analyses using synthetic phosphopeptides corresponding to the ITIM of Fc␥RIIb (16) and in in vivo analyses by co-immunoprecipitation experiments under special conditions of cell stimulation (17) . However, no functional role for SHP-1 in Fc␥RIIb-mediated inhibition has thus far been identified. Indeed, experiments in B cells expressing chimeric receptors with the extracellular domain of Fc␥RIIb fused to either SHIP or SHP-1 indicated that SHP-1 plays no role in Fc␥RIIb-mediated inhibition of the B cell antigen receptor signaling (8) .
In this report we demonstrate for the first time the presence of Fc␥RIIb in human monocytes using a novel anti-Fc␥RIIb rabbit polyclonal antibody. Interestingly, the expression of Fc␥RIIb in human monocytes is not constant, but is highly regulated by factors such as density of cell culture and the presence of the inflammatory cytokines such as interleukin-4 in the surrounding milieu. We have further characterized the function of Fc␥RIIb in human monocytes and provide evidence that this receptor plays an inhibitory role in Fc␥R-mediated monocyte/macrophage function. Thus, co-clustering Fc␥RIIb with the ITAM-bearing Fc␥RIIa resulted in enhanced phosphorylation of SHIP, association of SHIP with Shc along with a concomitant decrease in Akt activation. Finally, we report that IL-4-induced up-regulation of Fc␥RIIb results in a loss of phagocytic efficiency of THP-1 cells, strongly supporting an inhibitory role for this receptor.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents-Anti-Fc␥RII mAb IV.3 Fab and IV.3 intact IgG were obtained from Medarex (Annandale, NJ). Anti-CD32 mAb FLI8.26 was from Pharmingen (San Diego, CA). Anti-phosphotyrosine antibody 4G10 was from UBI (Lake Placid, NY). Anti-SHIP rabbit polyclonal antibody was a kind gift from Dr. K. Mark Coggeshall (Oklahoma Medical Research Foundation, Oklahoma City, OK). Anti-Akt and AntipAkt were from New England Biolabs (Beverley, MA). Goat F(abЈ) 2 antimouse IgG was from Pierce. Protein G-agarose beads were from Invitrogen (Rockville, MD). N-Glycosidase F was purchased from Roche Molecular Biochemicals. Anti-Fc␥RII mAb KB61 was obtained from Dr. D. Mason, Oxford, UK. Anti-Fc␥RIIb rabbit polyclonal antibody, Ab163, was from Dr. Jean-Luc Teillaud, and was raised against a glutathione S-transferase fusion protein of the cytoplasmic tail of Fc␥RIIb1. All Fc␥RII antibodies used have been previously described (40) .
Cells and Cell Culture-THP-1, U937 (monocytic cell lines), and Raji B cells were obtained from ATCC. IIA1.6 cells were a kind gift from Dr. Ira Mellman. The IIA1.6ϩIIa were obtained from Dr. Jan G. J. Van de Winkel. All cells were maintained at 37°C in RPMI supplemented with 10% heat-inactivated fetal bovine serum and 5% CO 2 .
Peripheral blood monocytes (PBM) were purified from buffy coats of healthy donors as described previously (18) . Briefly, peripheral blood mononuclear cells (PBMCs) were first isolated by density gradient centrifugation over Histopaque (Sigma). Monocytes were then purified from the PBMCs by negative selection using the MACs Monocyte Isolation Kit (Miltenyi Biotech). PBMCs were then treated with FcR blocking reagent (hIgG), followed by a hapten-antibody mixture (mixture of monoclonal hapten-conjugated CD3, CD7, CD19, CD45RA, CD56, and anti-IgE antibodies). The labeled cells were further treated with MACS anti-hapten magnetic microbeads that were conjugated to a monoclonal anti-hapten antibody. The cells were then passed over a MACS column, and the effluent was collected as the negative fraction representing enriched monocytes. The monocytes thus purified were subsequently analyzed for purity by double labeling with CD14-phycoerthrin and CD45-fluorescein isothiocyanate antibodies followed by flow cytometry. Data from 10,000 cells indicated that the isolated monocytes were Ͼ99% CD14 positive.
Cell Stimulation and Lysis-For activation, 10 7 cells per sample were resuspended in 100 l of HBSS, incubated with 10 g/ml IV.3 Fab, IV.3, or FL18 for 25 min at 4°C. The unbound antibody was washed off, cells were resuspended again in 100 l of HBSS and treated with F(abЈ) 2 goat anti-mouse IgG for the desired time periods at 37°C. Resting and activated cells were lysed in TN1 lysis buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 10 mM Na 4 P 2 O 7 , 10 mM NaF, 1% Triton X-100, 125 mM NaCl, 3 mM Na 3 VO 4 , 10 g/ml each aprotinin and leupeptin, and 2 mM phenylmethylsulfonyl fluoride) for 30 min on ice.
Immunoprecipitation and Immunoblotting-Postnuclear lysates were incubated overnight with the antibody of interest and protein G-agarose beads (Invitrogen) or goat anti-mouse Ig covalently linked to agarose, depending on the immunoprecipitating antibody. Immune complexes bound to beads were washed in TN1 and boiled in SDS sample buffer (60 mM Tris, pH 6.8, 2.3% SDS, 10% glycerol, 0.01% bromphenol blue, and 1% 2-mercaptoethanol) for 5 min. Proteins were separated by SDS-PAGE, transferred to nitrocellulose filters, probed with the antibody of interest, and developed by enhanced chemiluminescence.
Immunoblot Data Quantitation-The ECL signal was quantitated using a scanner and a densitometry program (Scion Image). The nonlinearity of ECL signal and the low dynamic range of the film used was corrected by generating a calibration curve for the experiments by serial dilution of a control sample, and film exposure time was varied to include the entire range of data. To quantitate the phosphotyrosine signal in the activated samples, we first subtracted background, normalized the signal to the amount of precipitated protein, and plotted the values obtained by subtracting the value in unstimulated samples.
Deglycosylation-Fc␥RII were immunoprecipitated from THP-1, U937, PBM, and Raji cells with a mixture of anti-Fc␥RII antibodies (equal amounts of AT10, KB61, and IV.3), washed in TN1 lysis buffer, and eluted by boiling in 30 l of 0.7% SDS for 5 min. The eluates were treated with either the enzyme diluent alone or with N-Glycosidase F at 37°C overnight. The enzyme reaction was stopped by boiling in SDS sample buffer.
Preparation of IgG-coated sheep RBCs-Sheep RBCs (Colorado Serum, Denver, CO) were washed in PBS, and labeled overnight with 0.1 mg/ml fluorescein isothiocyanate in PBS at 4°C. Fluorescein isothiocyanate-labeled cells were then washed in PBS and incubated with a subagglutinating dose of rabbit anti-sheep RBC IgG (Diamedix, Miami, FL) at 37°C for 1 h. Unbound IgG was removed by washing the cells with PBS.
Phagocytosis Assay-IgG-coated SRBCs described above were added to THP-1 cells in suspension, and the cells were pelleted by low speed centrifugation to increase contact between SRBCs and phagocytes. The samples were prepared in duplicate and incubated for 1 h at either 4°C to study binding, or 37°C to study phagocytosis. All cells were fixed in 1% paraformaldehyde and mounted on slides to be viewed under a fluorescence microscope. For the phagocytosis assay, cells were subjected to brief hypotonic lysis with water to get rid of externally bound RBCs prior to fixation in paraformaldehyde. The ability of the THP-1 cells to bind IgG-coated targets was expressed as the percentage of cells that each bound three or more SRBCs (rosetting activity, Phagocytosis via Fc␥RIIa alone or via Fc␥RIIa and Fc␥RIIb was performed as described previously (39) . Briefly, THP-1 cells were labeled with either IV.3Fab or FLI8 antibodies for 25 min on ice. Unbound antibody was washed off in PBS and the cells were resuspended in PBS. SRBC were first fluoresceinated as described above and subsequently biotinylated with n-hydroxysuccinimidi-LC-biotin. The biotinylated SRBC were then incubated with 200 g/ml streptavidin and washed in PBS before adding 40 g/ml biotinylated F(abЈ) 2 of goat anti-mouse IgG. The SRBCs thus prepared were then mixed with mAblabeled THP-1 cells and the phagocytosis assay was performed as described above.
RESULTS

Fc␥RIIb Is Expressed in Human Monocytes and Monocytelike Cell
Lines-To assess the presence of Fc␥RIIb protein in human PBMs and in THP-1 and U937 monocyte-like cell lines we used a novel rabbit polyclonal antibody, Ab163, raised against the cytoplasmic tail of Fc␥RIIb (40) . Although the extracellular and transmembrane domains are similar, the cytoplasmic tail of Fc␥RIIa and Fc␥RIIb are largely divergent with the exception of the first 8 amino acid residues thus allowing the production of Fc␥RIIb-specific antibody. In these experiments Fc␥RII was immunoprecipitated with a mixture of antiFc␥RII mAbs, the immune complexes were separated by SDS-PAGE and subjected to immunoblotting with either an Fc␥RIIa-specific antibody (Ab260) (Fig. 1A, upper panel) , or the anti-Fc␥RIIb antibody (Ab163) (Fig. 1A, lower panel) 7 cells were used immunoblotting with Ab260, whereas 4 ϫ 10 7 cells were used for immunoblotting with Ab163. Results indicated the presence of Fc␥RIIb in PBMs, THP-1, and U937 cells. The amount of IIb present in U937 cells appeared much lower than that in PBMs and THP-1 cells. Additionally we noted the presence of a doublet in the PBMs and Raji cells that reacted with Ab163, perhaps representing either differentially glycosylated forms and/or the b1 and b2 isoforms of the receptor; b1 migrates more slowly owing to a 19-amino acid insertion in its cytoplasmic tail (3). THP-1 and U937 cells also exhibited the doublet after deglycosylation (see below).
Both b1 and b2 Isoforms of Fc␥RIIb Are Expressed in Human
Monocytes-In the absence of glycosylation, the mobility of Fc␥RIIb1 differs from that of b2 in SDS-PAGE (3). Thus, to determine which of the isoforms of Fc␥RIIb are present in monocytes, Fc␥RII immunoprecipitates were deglycosylated with N-glycosidase F, separated by SDS-PAGE, and immunoblotted with Ab260 (Fig. 1B, upper panel) , or with Ab163 (Fig.  1B, lower panel) . Deglycosylation reduced both Fc␥RIIa and IIb to around 30 -35 kDa, the reported size of the core proteins. Results indicated that both the b1 and b2 isoforms of Fc␥RIIb are present in all cells tested. The finding that both isoforms are present in U937 and Raji cells is consistent with an earlier report that demonstrated the presence of these isoforms by RT-PCR (2). Our data (Fig. 1B, lower panel) also indicated that b2 is the predominant isoform expressed in PBMs and U937 cells, whereas b1 is the major isoform expressed in Raji B cells; these observations are consistent with earlier reports analyzing Fc␥RIIb1 and b2 mRNA levels in these cells (2, 19) . Such a distinction between the levels of expression of the Fc␥RIIb1 and b2 was not so evident in THP-1 cells.
Expression of Fc␥RIIb in Human Monocytes
Is RegulatedPrevious studies have shown that Fc receptor expression is regulated by cytokines (20 -22) . However, no information exists regarding the regulation of Fc␥RIIb expression. Based on the fact that Th1 cytokines enhance macrophage responses while Th2 cytokines inhibit the same, we hypothesized that the above effect could be a reflection of the influence of these cytokines on the expression of activating versus inhibitory Fc␥R. Consistent with this notion it has long been known that treatment of monocytes with IFN␥, a Th1 cytokine, results in a significant up-regulation of the expression of the ITAM-associated Fc␥RI receptors (20) . Here, we undertook to analyze the effect of IL-4, a Th2 cytokine, on the expression of Fc␥RIIb and Fc␥RIIa. Thus, U937 cells were cultured in increasing concentrations of recombinant hIL-4 for 24 h (Fig. 2A) . The expression of Fc␥RIIb and IIa in these cells was then analyzed by immunoblotting. U937 cells, which express the least amount of Fc␥RIIb among the monocyte-like cells tested, were chosen for this experiment as we reasoned that a regulatory effect on the expression of Fc␥RIIb would be more evident on a background of low level expression of the receptor. Results indicated that the presence of IL-4 had no effect on the expression of Fc␥RIIa (Fig. 2A,  lower panel) . In contrast, the expression of Fc␥RIIb was significantly enhanced by all doses of IL-4 ( Fig. 2A, upper panel) . The enhancing effect of IL-4 on Fc␥RIIb expression was also observed in PBMs (Fig. 2B ) and in THP-1 cells (Fig. 5B) .
During the course of our investigations we observed that the expression of Fc␥RIIb varied based on the density of the cell culture. To formally address this, U937 cells were seeded at the 3 densities indicated in Fig. 2C and cultured for 24 h. Fc␥RII receptors were immunoprecipitated from lysates of equal number of cells from the three different cultures with the antiFc␥RII mixture described above, and probed by immunoblotting with either Ab163 (upper panel) or Ab260 (lower panel). Results indicated that as the cell density decreased, the amount of Fc␥RIIb decreased dramatically. Densitometry measurements of band intensities indicated that the amount of protein reactive with Ab163 was 70% reduced in lane 2, and 95% reduced in lane 3 when compared with lane 1 (Fig. 2C) . In contrast, in the duplicate blot probed with Ab260 the amount of Fc␥RIIa remained unaltered verifying, at the very least, that all lanes were loaded with equal numbers of cells. This trend was consistently observed in three other experiments.
Co-clustering Fc␥RIIb with Fc␥RIIa Enhances the SHIP Phosphorylation, SHIP-Shc Association, and the Phosphorylation of 120-and 60 -65-kDa Molecules-Next we examined the function of Fc␥RIIb in human monocytes. Fc␥RIIb has been shown to serve as an inhibitory receptor when co-clustered with the B cell antigen receptor (23) . The inhibitory influence of Fc␥RIIb has been demonstrated to work via the phosphorylation and activation of the inositol phosphatase SHIP (8) . In B cells, co-clustering B cell antigen receptor and Fc␥RIIb upregulates the tyrosine phosphorylation of SHIP, the association of SHIP with the adapter protein Shc (24) , as well as the tyrosine phosphorylation of Shc itself (25) . While a direct role for Fc␥RIIb in human monocytes has not been established, co-transfection experiments of Fc␥RIIa and IIb in COS-7 cells revealed that Fc␥RIIb may serve to inhibit the phagocytic process initiated by Fc␥RIIa (26). Hence we wished to examine the signaling processes induced by co-clustering Fc␥RIIb with IIa. In these experiments we used either the Fab fragments of mAb IV.3 and GAM to specifically cluster Fc␥RIIa or IV.3 intact IgG and GAM to co-cluster Fc␥RIIa and IIb. The rationale for this usage is that IV.3 is of the murine IgG2b isotype that is reported to have a fairly high capability of serving as a ligand for Fc␥RIIb (27) and could therefore potentially recruit Fc␥RIIb. In addition to these antibodies we also used the pan Fc␥RII mAb FL18.26, which interacts equally well with both Fc␥RIIa and IIb (28) . Thus, THP-1 cells were activated by clustering the Fc␥RII receptors with the above antibodies, and the ensuing signaling events were analyzed.
First, tyrosine phosphorylation of SHIP was examined in THP-1 cells that had been activated with IV.3 Fab, IV.3 intact IgG, or with FLI8. 26 . Results show that co-clustering Fc␥RIIb with IIa enhanced SHIP phosphorylation (Fig. 3A, upper panel,  lanes 4 and 5) . A reprobe of the same membrane with anti-SHIP antibody showed equal loading of SHIP in all lanes (lower panel). Asking whether the enhancement of SHIP phosphorylation by IV.3 intact IgG and FLI8.26 was a consequence of Fc␥RIIb-IIa co-clustering, or simply a reflection of these antibodies clustering more Fc␥RIIa receptors, we employed a supplementary approach clustering IIa in cells expressing no IIb. For this we used the IIA1.6 mouse B cells that lack Fc␥RIIb but have been stably transfected to express human Fc␥RIIa. These cells were activated by methods described above and the resultant SHIP phosphorylation was analyzed by immunoblotting with anti-phosphotyrosine antibody. As seen in Fig. 3B , upper panel, in the absence of Fc␥RIIb, SHIP phosphorylation induced by all three antibodies was equivalent. These results strongly suggest that the enhancement of SHIP phosphorylation observed in THP-1 cells activated with IV.3 intact IgG or FLI8.26 is not a consequence of differences in the capacities of the anti-Fc␥RIIa antibodies to cluster Fc␥RIIa, but rather is likely the consequence of recruiting Fc␥RIIb into a complex with Fc␥RIIa.
We next asked whether co-clustering Fc␥RIIb-IIa would also enhance Shc phosphorylation (25) and SHIP-Shc association (24, 29) , as reported in other cell systems following antigen receptor co-clustering with Fc␥RIIb. Here, we immunoprecipitated Shc from lysates of THP-1 cells activated as described above and probed the membrane with anti-phosphotyrosine antibody. Results indicated that both Shc phosphorylation and SHIP-Shc association are indeed enhanced under conditions of Fc␥RIIa-IIb co-clustering (Fig. 3C, upper panel, lanes 3 and 4) . The same membrane was reprobed with anti-Shc antibody to ensure equal loading of Shc in all lanes (lower panel). Interestingly, an anti-phosphotyrosine blot of whole cell lysates from THP-1 cells activated as above, by clustering either Fc␥RIIa alone or by co-clustering Fc␥RIIa with IIb, revealed additional molecules that displayed enhanced phosphorylation under conditions of co-clustering (Fig. 3D) . Specifically, proteins in the molecular weight range of 120,000 and 60,000 -65,000 were apparently phosphorylated more efficiently by Fc␥RIIb-IIa coclustering than by Fc␥RIIa clustering alone. Although the identity of these proteins is not known, we speculate that the 120-kDa protein is probably Cb1. The band seen around 60 -65 kDa could represent the protein-tyrosine phosphatase SHP-1 and/or the RasGAP-binding protein p62
dok . All of the above proteins serve inhibitory roles in other cell types (30 -32) . Studies are underway to determine the identity of these proteins.
Co-clustering Fc␥RIIb with Fc␥RIIa Down-regulates Akt Phosphorylation and Concomitantly
Increases SHIP Phosphorylation-We next examined the influence of Fc␥RIIb-IIa coclustering on the activation of the Akt. Akt is a serine/threonine kinase that serves to protect cells from apoptosis. Activation of Akt requires the binding of the plextrin homology domain of Akt to PtdIns(3,4,5)P 3 and the phosphorylation of Akt on serine/threonine residues (33) . Recent studies indicated that hydrolysis of PtdIns(3,4,5)P 3 by SHIP attenuates Akt activation in B cells (14, 15) . Since co-clustering Fc␥RIIa-IIb correlates with SHIP activation in human monocytes we undertook to determine whether Akt activation was down-regulated under the same conditions. To do this we first examined the ability of Fc␥RIIa to activate Akt. Activation of Akt by Fc␥RIIa clustering in neutrophils, but not monocytes, has been previously reported (34) . Thus, THP-1 cells were activated for various time periods as indicated in SHIP phosphorylation was analyzed by immunoblotting anti-SHIP immunoprecipitates with anti-phosphotyrosine antibody. Phosphorylation levels of Akt and SHIP, quantified by laser densitometry, are illustrated graphically as fold increases over that observed in unstimulated cells (Fig. 4B) . Remarkably, phosphorylation of Akt declined under conditions of Fc␥RIIb-IIa co-clustering while phosphorylation of SHIP increased under the same conditions. 
Up-regulation of Fc␥RIIb Expression Decreases Phagocytic
Efficiency in THP-1 Cells-Fc␥RIIb is reported to attenuate phagocytic efficiency of murine macrophages (1). To determine whether Fc␥RIIb might similarly decrease the ability of human macrophages to phagocytose IgG-opsonized particles, we tested the Fc␥R-mediated phagocytic capacity of monocytic cells cultured with and without IL-4. THP-1 cells were first cultured in IL-4 for 24 h. Expression of Fc␥RIIb in these cells was upregulated as confirmed by immunoblotting, while no significant effect was seen in the expression of Fc␥RIIa (Fig. 5B) . We then measured the ability of THP-1 cells, cultured in the presence or absence of IL-4, to bind and phagocytose fluoresceinated IgGopsonized sheep red blood cells (EA) by methods described previously by our laboratory (18) . Results indicated that the overall percent of THP-1 cells that bound 3 or more SRBC (rosetting activitiy) were equivalent, regardless of whether the cells were cultured in IL-4 (Fig. 5A, top panel) . However, the THP-1 cells that were cultured in IL-4 consistently bound a greater number of RBC (adherence index) than the THP-1 cells that were cultured without IL-4, consistent with the up-regulated expression of Fc␥RIIb in these cells (middle panel). In contrast, the phagocytic capacity of THP-1 cells cultured in the presence of IL-4 was diminished by 40% in comparison to the THP-1 cells that were not cultured with IL-4. These results suggest an inhibitory role for Fc␥RIIb.
To test whether the decrease in phagocytic efficency displayed by THP-1 cells cultured in the presence of IL-4 was indeed due to the inhibitory effects of Fc␥RIIb, we measured phagocytosis via either Fc␥RIIa alone or via Fc␥RIIa and Fc␥RIIb as described under "Experimental Procedures." mediated activation of monocytic cell function. Our data also indicate that the expression of Fc␥RIIb in human monocytic cells is highly regulated. Taken together these observations suggest that Fc␥RIIb serves as a modulator of monocyte response such that the level of expression of Fc␥RIIb is inversely proportional to the magnitude of the response. The identification of this receptor reveals a regulatory mechanism that has thus far not been demonstrated in human monocytic cells.
The function of Fc␥RIIb in B cells (11, 23) and mast cells (35) , where it is the only Fc␥R expressed, has been extensively studied. However, in monocytic cells the presence of multiple Fc␥R has prevented the functional analysis of Fc␥RIIb in isolation. In human monocytes the expression of Fc␥RIIa whose extracellular and transmembrane domains are virtually identical to Fc␥RIIb has further complicated the study of this receptor. In this study we took advantage of a novel Fc␥RIIb-specific antibody, Ab163, to first identify the receptor in human monocytic cells. Earlier work from our laboratory reported the inability to detect Fc␥RIIb in U937 cells using the only available Fc␥RIIb-specific mAb, II8D2 (36) . With the use of Ab163 we demonstrate here the presence of Fc␥RIIb in PBMs as well as in the monocyte-like cell lines U937 and THP-1. It is noteworthy, however, that the detection of this receptor required the use of detergent lysates from four times the number of cells used to detect Fc␥RIIa, suggesting that Fc␥RIIb is present in very low levels in these cells.
Using a combination of antibodies that recognize either Fc␥RIIa alone or share a common epitope on Fc␥RIIa and IIb, we have further characterized the function of this receptor in Fc␥R-mediated signaling. Fab fragments of mAb IV.3 were used to specifically cluster Fc␥RIIa alone. To co-cluster Fc␥RIIa with IIb we employed two approaches: first, IV.3 intact IgG was chosen since it could recruit Fc␥RIIb by a ligand interaction owing to the fact that this antibody is of the murine IgG2b isotype, which has a measurable affinity for the otherwise low affinity Fc␥RIIb receptor (27) . It is unlikely that the IV.3 intact IgG could have served as a ligand for Fc␥RI since this receptor has very low affinity for mIgG2b (37) . As a second approach, we used mAb FLI8.26, which is also of the murine IgG2b isotype, and recognizes both Fc␥RIIa and IIb equally well as antigen. The latter method of co-clustering was more effective at inducing negative signaling events in monocytic cells. That IV.3 intact IgG and FLI8.26 do indeed recruit Fc␥RIIb is demonstrated in that receptor clustering with these antibodies in cells expressing Fc␥RIIa but not IIb (IIA1.6ϩIIa) did not induce enhanced SHIP phosphorylation. Furthermore, activation of THP-1 cells with IV.3 intact or FLI8.26 led to decreased Akt phosphorylation while concomitantly leading to an enhancement of SHIP phosphorylation under the same conditions of activation. Maximal SHIP phosphorylation and inhibition of Akt phosphorylation was achieved with FLI8.26, confirming that the use of this antibody is a more effective way to co-cluster Fc␥RIIa-IIb, in comparison to co-clustering with IV.3 intact IgG. Thus these experiments provide compelling evidence that in monocytic cells Fc␥RIIb functions to down-regulate ITAM-Fc␥R mediated signaling events.
It must be noted, however, that it is not clear whether the inhibitory effects are mediated by Fc␥RIIb1, b2, or by both. Although the b1 and b2 forms of Fc␥RIIb differ in that b1 has a 19-amino acid insertion in its cytoplasmic tail, they both express the ITIM and are, therefore, likely to function in a similar manner with respect to the induction of SHIP activation and other associated negative signaling events. However, this point requires formal testing.
We have analyzed the role of IL-4 in Fc␥R-mediated phagocytosis. Our results indicated that THP-1 cells cultured in the presence of IL-4 display enhanced expression of Fc␥RIIb with an associated decrease in phagocytic efficiency. We suggest that the reduced phagocytic efficiency is not the result of a decrease in the expression of ITAM-Fc␥R in the THP-1 cells cultured with IL-4 since in our hands there was no detectable decrease in the expression of Fc␥RIIa or Fc␥RI. To determine whether the IL-4-mediated increase in the negative regulation of Fc␥R activation was directly due to the up-regulation of Fc␥RIIb, we analyzed the phagocytosis via Fc␥RIIa alone or via Fc␥RIIa-IIb in THP-1 cells cultured in the presence or absence of IL-4. As seen in Fig. 5C phagocytosis by Fc␥RIIa clustering is not significantly different in cells cultured with or without IL-4, indicating that IL-4 has no effect on Fc␥RIIa signaling. In contrast, the inhibition of phagocytosis by Fc␥RIIa-IIb co-clustering is enhanced in cells cultured with IL-4. We interpret these results to indicate that the enhanced inhibition of Fc␥R-mediated activation in cells cultured with IL-4 is directly due to the up-regulation of Fc␥RIIb.
The expression of Fc␥RIIb appears to be very highly regulated not only by the presence of inflammatory cytokines, such as IL-4, but also by culture conditions, such as density of cell culture and passage number of the culture. Thus, in our hands, expression of Fc␥RIIb increased as cell density was increased. Likewise, Fc␥ RIIb expression was also up-regulated in later passages of the cell culture (data not shown). Studies to identify specific factors in the culture medium that relate to modulation of Fc␥RIIb expression are currently in progress.
Finally, an understanding of factors that regulate the expression of Fc␥RIIb is of considerable importance based on the recent observations of Clynes et al. (38) analyzing the influence of Fc␥R on the efficacy of therapeutic anti-tumor antibodies. Using mice that were genetically engineered to be deficient in the expression of either the FcR ␥-chain or Fc␥RIIb they elegantly demonstrated that the presence of Fc␥RIIb down-regulates the efficacy of the therapeutic antibodies. These observations suggest that the ratio of ITAM-Fc␥R to ITIM-Fc␥R is critical to the magnitude of any IgG-mediated immune response. Identification of factors that influence the expression of these receptors can, therefore, potentially allow us to vary the levels of Fc receptor expression to achieve the desired immune response.
Similar findings regarding the effect of IL-4 on the expression on Fc␥RIIb in human monocytes were reported while our manuscript was in review (41) . These studies, however, in contrast to our observations were unable to detect the expression of Fc␥RIIb in U937 cells.
